Early negative experiences with sotorasib combinations with PD-(L)1 blockade indicate that there will be many more hurdles to overcome and much more to learn about the underlying biology, but it is undeniable that there is huge potential in combining the orthogonal approaches of targeting KRAS signaling together with reactivating the immune system against the tumor. Here, KRAS is linked to neoplasm.